High-rolling investors have positioned themselves bearish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRSP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for CRISPR Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 18% bullish and 81% bearish. Among all the options we identified, there was one put, amounting to $26,700, and 10 calls, totaling $887,198.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $80.0 for CRISPR Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 662.62 with a total volume of 4,063.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $50.0 to $80.0 over the last 30 days.
CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | TRADE | NEUTRAL | 04/19/24 | $75.00 | $384.0K | 1.3K | 1.5K |
| CRSP | CALL | SWEEP | BEARISH | 04/19/24 | $75.00 | $155.0K | 1.3K | 901 |
| CRSP | CALL | SWEEP | NEUTRAL | 01/17/25 | $80.00 | $103.9K | 2.2K | 100 |
| CRSP | CALL | TRADE | BULLISH | 01/05/24 | $63.00 | $60.0K | 272 | 448 |
| CRSP | CALL | TRADE | BEARISH | 03/15/24 | $70.00 | $35.0K | 369 | 78 |
About CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Present Market Standing of CRISPR Therapeutics
- With a volume of 2,305,585, the price of CRSP is down -1.23% at $61.83.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 49 days.
Professional Analyst Ratings for CRISPR Therapeutics
5 market experts have recently issued ratings for this stock, with a consensus target price of $83.0.
- An analyst from TD Cowen downgraded its action to Underperform with a price target of $30.
- An analyst from Truist Securities persists with their Buy rating on CRISPR Therapeutics, maintaining a target price of $160.
- Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on CRISPR Therapeutics with a target price of $80.
- An analyst from RBC Capital has decided to maintain their Sector Perform rating on CRISPR Therapeutics, which currently sits at a price target of $57.
- An analyst from Needham persists with their Buy rating on CRISPR Therapeutics, maintaining a target price of $88.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
